Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become an important and accepted therapeutic treatment for malignant disorders. Hematopoietic stem cells can be obtained from bone marrow through multiple aspirations or alternatively from peripheral blood after stimulation with granulocyte colony-stimulating factor (G-CSF). G-CSF has been indicated to promote the mobilization and differentiation of hematopoietic stem cells and is now a widely used scheme in HSCT [1]. However, the mobilization efficiency of G-CSF varies individually; that is, poor mobilization occurs in 25% of patients with hematological malignancies and in 10%-20% of healthy donors [2].
G-CSR is a highly specific receptor that binds G-CSF and induces a series of signaling cascades, leading to different biological events[3,4]. Genomic sequencing of the CSF3R locus has identified many intronic polymorphisms and four synonymous coding mutations [5], therefore discrepancies in the CSF3R gene, whether caused by SNPs or mutations, that have been proven to be associated with an abnormal response to G-CSF treatment[6,7,8]. However, most current studies focus on the effect of CSF3R polymorphisms on the occurrence or progression of disease in patients [9]. Donor-derived hematopoietic stem cells are the products responding to G-CSF treatment. Bahar et al used PCR-RFLP technology to study whether differences in CSF3R SNP loci of healthy donors and hematological tumor patients would affect the enrichment of peripheral blood CD34+ cells, and the results showed that different SNP loci have different mobilization efficiencies for different individuals. Among them, healthy donors carrying the rs3918018 A/A genotype had significantly less efficient CD34 + collections in the first two attempts than donors carrying the G/G genotype [10]. Since the number of CD34 molecules is related to cell implantation, reconstruction and other events post allo-HSCT and CSF3R polymorphism may directly affect the prognosis of transplantation, whether the clinical prognosis of patients after HSCT will be affected by donor CSF3R polymorphisms has not yet been elucidated. Thus, the aim of the study was to screen CSF3R SNPs and therefore explore whether donor CSF3R SNPs can affect the clinical outcomes of patients post allo-HSCT.